Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.
Yang Y, Min J, Yang N, Yu Q, Cheng Y, Zhao Y, Li M, Chen H, Ren S, Zhou J, Zhuang W, Qin X, Cao L, Yu Y, Zhang J, He J, Feng J, Yu H, Zhang L, Fang W. Yang Y, et al. Signal Transduct Target Ther. 2023 Aug 14;8(1):301. doi: 10.1038/s41392-023-01538-w. Signal Transduct Target Ther. 2023. PMID: 37574511 Free PMC article. Clinical Trial.
This phase III trial (ClinicalTrials.gov NCT04009317) investigated the efficacy and safety of first-line envonalkib in advanced ALK-positive NSCLC cases. Totally 264 participants were randomized 1:1 to receive envonalkib (n = 131) or crizotinib (n = 133). ...Envo …
This phase III trial (ClinicalTrials.gov NCT04009317) investigated the efficacy and safety of first-line envonalkib in advanced ALK-p …
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Zhao M, Shao T, Shao H, Zhou C, Tang W. Zhao M, et al. BMC Cancer. 2024 Feb 8;24(1):186. doi: 10.1186/s12885-024-11916-4. BMC Cancer. 2024. PMID: 38331773 Free PMC article.
RESULTS: A total of fourteen studies (ten for first-line, four for second-line) consisting of nine treatments (chemotherapy, crizotinib, alectinib [600mg BID], low-dose alectinib [300mg BID], brigatinib, ceritinib, ensartinib, envonalkib, and lorlatinib) were included. In …
RESULTS: A total of fourteen studies (ten for first-line, four for second-line) consisting of nine treatments (chemotherapy, crizotinib, ale …
Pharmacokinetics, mass balance, and metabolism of [(14)C]envonalkib (TQ-B3139), a novel ALK tyrosine kinase inhibitor, in healthy Chinese subjects.
Ma S, Wang X, Yan S, Miao L, Wan X, Ding D, Yu D, Diao X, Wang X, Zhang H. Ma S, et al. Cancer Chemother Pharmacol. 2024 Mar 20. doi: 10.1007/s00280-024-04647-7. Online ahead of print. Cancer Chemother Pharmacol. 2024. PMID: 38507062
This phase I mass balance study investigated the pharmacokinetics, metabolism, and excretion of (14)C-radiolabeled envonalkib in healthy Chinese male subjects. METHODS: A single oral dose of 600 mg (150 Ci) [(14)C]envonalkib was administered to healthy male subjects …
This phase I mass balance study investigated the pharmacokinetics, metabolism, and excretion of (14)C-radiolabeled envonalkib in heal …